Long-Term Efficacy of Adalimumab After Drug Withdrawal and Retreatment in Patients With Active Non-Radiographically Evident Axial Spondyloarthritis Who Experience a Flare-Reference-Cited by-同舟云学术

Long-Term Efficacy of Adalimumab After Drug Withdrawal and Retreatment in Patients With Active Non-Radiographically Evident Axial Spondyloarthritis Who Experience a Flare

Published:2013-07-26 Issue:8 Volume:65 Page:2211-2213
ISSN:0004-3591
Container-title:Arthritis & Rheumatism
language:en
Short-container-title:Arthritis & Rheumatism

Author:

Haibel H.¹,Heldmann F.²,Braun J.²,Listing J.³,Kupper H.⁴,Sieper J.⁵

Affiliation:

1. Charité Hospital, Campus Benjamin Franklin; Berlin Germany

2. Center of Rheumatology; Herne Germany

3. German Rheumatism Research Center; Berlin Germany

4. AbbVie Deutschland GmbH & Company KG; Ludwigshafen Germany

5. Charité Hospital, Campus Benjamin Franklin, and German Rheumatism Research Center; Berlin Germany

Publisher

Wiley

Subject

Pharmacology (medical),Immunology,Rheumatology,Immunology and Allergy

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1002/art.38014/fullpdf

Reference12 articles.

1. The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis. Part II. Validation and final selection;Rudwaleit;Ann Rheum Dis,2009

2. Evaluation of diagnostic criteria for ankylosing spondylitis: a proposal for modification of the New York criteria;Linden;Arthritis Rheum,1984

3. 2010 update of the international ASAS recommendations for the use of anti-TNF agents in patients with axial spondyloarthritis;Heijde;Ann Rheum Dis,2011

4. Efficacy of adalimumab in the treatment of axial spondylarthritis without radiographically defined sacroiliitis: results of a twelve-week randomized, double-blind, placebo-controlled trial followed by an open-label extension up to week fifty-two;Haibel;Arthritis Rheum,2008

5. Efficacy and safety of adalimumab in patients with ankylosing spondylitis: results of a multicenter, randomized, double-blind, placebo-controlled trial;Heijde;Arthritis Rheum,2006

Cited by 42 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Dose Tapering and Discontinuation of Biologic DMARDs in Axial Spondyloarthritis: A Narrative Review (2023 SPARTAN Annual Meeting Proceedings);Current Rheumatology Reports;2024-02-09

2. Occurrence and Prediction of Flare After Tapering of Tumor Necrosis Factor Inhibitors in Patients With Axial Spondyloarthritis;The Journal of Rheumatology;2023-10-15

3. To taper or not to taper biological disease-modifying antirheumatic drugs in axial spondyloarthritis anno 2023: That is the question;Best Practice & Research Clinical Rheumatology;2023-09

4. Estradiol is a key candidate for treating Ankylosing Spondylolisthesis with Traditional Chinese Medicine;Computers in Biology and Medicine;2023-09

5. Décroissance ou arrêt des traitements de fond biologiques dans la spondyloarthrite axiale : revue de la littérature;Revue du Rhumatisme;2023-05